Navigation Links
Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference
Date:4/22/2013

KING OF PRUSSIA, Pa., April 22, 2013 /PRNewswire/ -- Trevena, Inc. a clinical stage pharmaceutical company today announced that its President and CEO, Dr. Maxine Gowen will present at the 12th Annual Needham Healthcare Conference on May 1, 2013, 10:00am, at Grand Hyatt New York.  

Dr. Gowen will provide a detailed overview of the company's most advanced clinical programs which include TRV027, a biased ligand for the treatment of acute heart failure, which is currently in Phase 2 studies, and TRV130, in Phase 1b studies for acute pain where intravenous therapy is needed. First-in-man study results on the safety, tolerability, and pharmacology of TRV130 in healthy volunteers were recently presented at the American Academy of Neurology.

The complete slide presentation of Dr Gowen's presentation will be available on Trevena's website (www.trevenainc.com) under the About Trevena tab.

Dr. Gowen will be available for one-on-one meetings with the investment community during the conference. Please contact conference organizers to secure a meeting time.

About Trevena and Biased Ligands

Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines. GPCRs are the targets for at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR, to unlock new biology and avoid drug adverse effects.  The discovery platform is applicable to a wide range of druggable targets and diseases.  Trevena is based in King of Prussia, Pennsylvania and is backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company.

CONTACT: Kimberly Minarovich , 917-533-3268, kminarovich@christensenir.com


'/>"/>
SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmagen to Present Strategic Vision for Solving Nations Parenteral Drug Shortage Crisis at 2013 BIO International Convention
2. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
3. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
4. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
5. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Cantel Medical To Present At Needham 12th Annual Healthcare Conference
8. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
9. Soligenix to Present at World Vaccine Congress & Expo
10. 20+ SynCardia Certified Centers to Present Record Number of Total Artificial Heart Abstracts at ISHLT
11. Novocure Presents Preclinical Data at the American Association for Cancer Research (AACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):